2. Search Result
Search Result
Results for "

facioscapulohumeral dystrophy

" in MedChemExpress (MCE) Product Catalog:

4

Inhibitors & Agonists

2

Inhibitory Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P990993
    Emugrobart

    GYM-329, RG6237, RG-70240

    		 TGF-beta/Smad Inflammation/Immunology
    Emugrobart (GYM-329, RG6237, RG-70240) is a humanized IgG1κ antibody targeting myostatin (Myostatin; GDF8). Emugrobart binds to pro-myostatin and latent myostatin, blocking their cleavage into mature myostatin; it also has a clearance function, which transports bound myostatin for degradation and allows for cyclic reuse. Emugrobart enhances muscle strength in mouse models of muscle atrophy and increases muscle mass in cynomolgus monkeys. Emugrobart can be used in research on spinal muscular atrophy and facioscapulohumeral muscular dystrophy .
    Emugrobart
  • HY-P99588
    Stamulumab
    1 Publications Verification

    MYO-029

    		 TGF-β Receptor Metabolic Disease
    Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
    Stamulumab
  • HY-177971
    Braxlosiran

    		Antibody-Oligonucleotide Conjugates (AOCs) Neurological Disease
    Braxlosiran, one of the components of the AOC Delpacibart braxlosiran (HY-177566), is composed of a siRNA targeting DUX4 (dual homologous box protein) and SMCC linker (HY-42360). Abnormal expression of the DUX4 protein leads to changes in gene expression in muscle cells, and these changes are associated with the loss of muscle function in facioscapulohumeral muscular dystrophy (FSHD) .
    Braxlosiran
  • HY-171277
    Casein kinase 1δ-IN-27

    		Casein Kinase p38 MAPK Cancer
    Casein kinase 1δ-IN-27 (Compound 8) is the inhibitor for casein kinase 1 that inhibits CK1α, CK1δ, CK1ε, and p38α with IC50s of 22, 16.5, 9.41 and 14.8 nM, respectively. Casein kinase 1δ-IN-27 inhibits the DUX4 expression with an IC50 of 10 nM .
    Casein kinase 1δ-IN-27

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: